Ipsen SA has discontinued development of its steroid sulfatase inhibitor, Irosustat, as a monotherapy for the treatment of hormone-dependent cancers. Instead it will explore development of the drug in combination with other hormonal therapies.
A consortium of Belgian academic scientists and biotechnology companies has recruited ImaginAb Inc of Los Angeles, California to work on a project to develop new diagnostic tools to monitor beta cell depletion in adult-onset diabetes.
Algeta ASA’s investigational radiopharmaceutical (radium-223 chloride) that is being developed by Bayer Schering Pharma AG, has met its primary endpoint in a Phase 3 trial of patients with prostate cancer and bone metastases.
André Mueller, a Swiss entrepreneur and chairman of the board of directors at Addex Pharmaceuticals Ltd, has become executive chairman of the company following the unexpected resignation of its chief executive, Vincent Mutel.
A Dutch molecular diagnostics company has announced plans to make an initial public offering of its shares on the NYSE Euronext exchange in Amsterdam to support the development and sales of its diagnostics.
In a major advance for personalised medicine, the UK Human Tissue Authority has authorised a new stem cell banking service that will extract adult stem cells from human blood samples and store them for up to 20 years for use against future disease.
Silence Therapeutics Plc has outlined plans for the early clinical development of its two lead cancer products following the successful completion of a share offering that raised £5.5 million, net of expenses, from existing and new shareholders.
Roche and Bristol-Myers Squibb Company have announced plans to investigate a combination of vemurafenib and ipilimumab in patients with BRAF-mutated metastatic melanoma. The two agents target the disease in different ways.
A spin-out of NV Philips Electronics that is developing brain stimulation technology has raised €13 million in a Series A financing round from Wellington Partners, Edmond de Rothschild Investment Partners and Life Sciences Partners.
Evotec AG is paying €10.25 million in cash upfront to acquire the US compound management business of Galápagos NV in a move that will substantially increase its ability to help third parties develop and manage their compound libraries.